Frontier IP Group - Portfolio news - Exscientia
Portfolio news - Exscientia: world's first clinical trials of new drug candidate created by Artificial Intelligence ("AI") started in joint development with Sumitomo Dainippon Pharma
A phase I clinical study of the drug candidate DSP-1181, designed to treat obsessive-compulsive disorder as an initial indication, has started in
Exscientia's other partnerships include collaborations with Bayer AG, Celgene, Sanofi, GT Apeiron, Rallybio and Evotec.
Exscientia statement in full:
Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Trial
Sumitomo Dainippon Pharma Co., Ltd. (Head office:
DSP-1181 was created through the joint research by Sumitomo Dainippon Pharma and Exscientia, with Sumitomo Dainippon Pharma providing its experience and knowledge in monoamine GPCR drug discovery and Exscientia applying its Centaur Chemist™ Artificial Intelligence (AI) platform for drug discovery. This project was delivered by the strong synergy of the joint research, requiring less than 12 months to complete the exploratory research phase, just a fraction of the typical average of 4.5 years using conventional research techniques. ref)
DSP-1181 is being progressed as a long-acting and potent serotonin 5-HT1A receptor agonist, and its phase I clinical study to treat obsessive-compulsive disorder as an indication candidate. Through this, Sumitomo Dainippon Pharma has expanded its development pipeline to treat key unmet medical needs in the Psychiatry and Neurology area, one of the company's three focus research areas.
Monoamine GPCR drug discovery
Drug discovery targeting G protein-coupled receptor (GPCR), endogenous ligands of which are monoamine neurotransmitters such as serotonin, dopamine and norepinephrine
OCD is a psychiatric disorder characterized by the presence of obsessions (repetitive and persistence thoughts, images, or urges) and/or compulsions (repetitive behaviors or mental acts). OCD is associated with reduced quality of life as well as high levels of social and occupational impairment as a result of time-consuming (e.g., take more than 1 hour per day) by obsessions or compulsions. The mechanism of OCD has not been clarified, however dysfunction in the orbitofrontal cortex, anterior cingulate cortex, and striatum have been most strongly implicated. The number of patients in
Paul SM et al "How to improve R&D productivity: the pharmaceutical industry's grand challenge" Nature Review Drug Discovery 2010
Exscientia statement ends
| || |
T: 020 7332 2338
Company website: www.frontierip.co.uk
M: 07464 546 025
| || |
T: 0203 328 5656
Media enquires :
Company website: www.exscientia.co.uk
| || |
NOTES FOR EDITORS
About sumitomo dainippon pharma co., ltd
Sumitomo Dainippon Pharma defines its corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide". By pouring all our efforts into the research and development of new drugs, we aim to realize our corporate mission and provide innovative and effective pharmaceutical solutions to people not only in
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.
Exscientia's innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.
Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.
As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.
Exscientia is collaborating with several leading pharmaceutical and life sciences companies, has its headquarters in
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
ABOUT RNS REACH ANNOUNCEMENTS
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the
Quick facts: Frontier IP Group PLC
Market Cap: £27.62 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE